Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen Van Nuys

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
JAMA Internal Medicine|December 7, 2020
Variation in Biosimilar Uptake in Europe-ReplyAlice J Chen, Karen Van Nuys
JAMA Network Open|August 1, 2025
Formulary Restrictions and Relapse Episodes in Persons With Relapsing-Remitting Multiple SclerosisBarbara Blaylock, Karen Van Nuys, Geoffrey Joyce
JAMA|February 14, 2025
Cost Sharing for Preferred Branded Drugs in Medicare Part DErin Trish, Barbara Blaylock, Karen Van Nuys
The American Journal of Managed Care|May 22, 2020
Provider differences in biosimilar uptake in the filgrastim marketAlice J Chen, Rocio Ribero, Karen Van Nuys
JAMA|September 10, 2024
Pharmacy Benefit Manager Market Concentration for Prescriptions Filled at US Retail PharmaciesDima M Qato, Yugen Chen, Karen Van Nuys
JAMA Health Forum|February 6, 2026
Pharmacy Benefit Manager Market Concentration for Prescriptions Filled at Retail Pharmacies by State and Payer TypeDima Mazen Qato, Yugen Chen, Karen Van Nuys
JAMA Health Forum|August 17, 2022
Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018Karen Van Nuys, Rocio Ribero, Martha Ryan, et al.
Health Affairs (Project Hope)|March 4, 2024
Medicare Part D Plans Greatly Increased Utilization Restrictions On Prescription Drugs, 2011-20Geoffrey Joyce, Barbara Blaylock, Jiafan Chen, et al.
JAMA Internal Medicine|July 24, 2020
Uptake of Infliximab Biosimilars Among the Medicare PopulationAlice J Chen, Laura Gascue, Rocio Ribero, et al.
JAMA|March 15, 2018
Frequency and Magnitude of Co-payments Exceeding Prescription Drug CostsKaren Van Nuys, Geoffrey Joyce, Rocio Ribero, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
JAMA Internal Medicine|December 7, 2020
Variation in Biosimilar Uptake in Europe-ReplyAlice J Chen, Karen Van Nuys
JAMA Network Open|August 1, 2025
Formulary Restrictions and Relapse Episodes in Persons With Relapsing-Remitting Multiple SclerosisBarbara Blaylock, Karen Van Nuys, Geoffrey Joyce
JAMA|February 14, 2025
Cost Sharing for Preferred Branded Drugs in Medicare Part DErin Trish, Barbara Blaylock, Karen Van Nuys
The American Journal of Managed Care|May 22, 2020
Provider differences in biosimilar uptake in the filgrastim marketAlice J Chen, Rocio Ribero, Karen Van Nuys
JAMA|September 10, 2024
Pharmacy Benefit Manager Market Concentration for Prescriptions Filled at US Retail PharmaciesDima M Qato, Yugen Chen, Karen Van Nuys
JAMA Health Forum|February 6, 2026
Pharmacy Benefit Manager Market Concentration for Prescriptions Filled at Retail Pharmacies by State and Payer TypeDima Mazen Qato, Yugen Chen, Karen Van Nuys
JAMA Health Forum|August 17, 2022
Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018Karen Van Nuys, Rocio Ribero, Martha Ryan, et al.
Health Affairs (Project Hope)|March 4, 2024
Medicare Part D Plans Greatly Increased Utilization Restrictions On Prescription Drugs, 2011-20Geoffrey Joyce, Barbara Blaylock, Jiafan Chen, et al.
JAMA Internal Medicine|July 24, 2020
Uptake of Infliximab Biosimilars Among the Medicare PopulationAlice J Chen, Laura Gascue, Rocio Ribero, et al.
JAMA|March 15, 2018
Frequency and Magnitude of Co-payments Exceeding Prescription Drug CostsKaren Van Nuys, Geoffrey Joyce, Rocio Ribero, et al.
Pageof 3